FRESENIUS MEDICAL CARE AG (FMS): what the price assumes

boothcheck covers FRESENIUS MEDICAL CARE AG (FMS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-26.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/FMS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.9% sits below it).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.2%); the inversion above states its own rate.

Per-Model Detail (n=17)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Dialysis is one of the rare businesses where a single company can build the machine, run the clinic the machine sits in and, in a growing slice of its U.S. work, take the insurance risk on the patient using it, and Fresenius Medical Care does all three across 3,539 clinics treating roughly 290,000 people.
• The prices are largely not its own to set: the FY2025 annual report states "A major portion of our revenues from healthcare are subject to reimbursement rates regulated by governmental authorities", and the return on invested capital it filed for the twelve months to March 2026 was 4.9 percent, less than the money funding it costs.
• The clearest near-term marker is capital return: a first tranche of up to 600 million euros under a fresh one billion euro buyback authorization began on May 28, 2026 and is expected to finish by December 15, 2026.

Bull Case

Three different businesses sit under this one ticker, and a single blended multiple flattens all of them. There is a manufacturer that makes dialysis machines and dialyzers. There is a clinic operator that treats patients on those machines. And there is a third arm, newer and smaller, that gets paid a fixed premium to keep kidney patients out of hospital and books the result under insurance-contract accounting. The FY2025 annual report describes the first two plainly: "As a vertically integrated medical technology (MedTech) and healthcare service company, Fresenius Medical Care combines medical device engineering and manufacturing expertise with comprehensive patient care." Very few healthcare companies own both ends of the same treatment.

Demand for that treatment does not negotiate. Around 4.5 million people worldwide undergo dialysis regularly, and this company treats roughly 290,000 of them through 3,539 clinics. A patient with failed kidneys goes three times a week or dies, which makes the volume line about as insensitive to the economic cycle as anything in healthcare. Competition outside the United States is unusually fragmented for a business of this size: the annual report notes that "In most countries other than the U.S., we compete primarily against individual freestanding clinics and hospital-based clinics." Against a single-site operator, a company that manufactures its own equipment has a cost position nobody local can replicate.

The turnaround underneath is real and it is recent. In the first quarter of 2026 revenue was 4,612 million euros, down 6 percent as reported but up 3 percent at constant exchange rates, with organic growth of 4 percent; Care Delivery contributed 3,294 million euros, Care Enablement 1,299 million and Value-Based Care 490 million. The products arm is the quiet story here. The annual report records that "Care Enablement recorded operating income as compared to an operating loss for the year ended December 31, 2023", so a division that was consuming profit is now producing it. Across the full prior year, the supervisory board chairman put organic revenue growth at 8 percent with improved margins and reduced leverage.

Then there is what management is doing with the cash, which is usually the most honest signal available. A one billion euro repurchase program was announced at a June 2025 capital markets day, its first tranche completed ahead of schedule on December 29, 2025, its second tranche of around 415 million euros pulled forward to run from January to May 2026. That program finished, shareholders approved a dividend of 1.49 euros a share and voted to cancel treasury stock outright, and a second one billion euro program opened its first tranche on May 28, 2026. Two consecutive billion-euro programs is a large commitment against a company whose entire market value is roughly 14.4 billion dollars. The bear will point out that buying back stock does not fix a low return on capital, and that is fair. It does, however, tell you what the people with the fullest view of the numbers think the shares are worth relative to a new clinic.

Bear Case

The clinics are rented. That sounds like a detail and it is not, because a dialysis network is essentially several thousand leases with medical equipment inside them, and the company's own capital-management measure treats those leases as borrowings. The annual report is explicit: "To determine the net leverage ratio, debt and lease liabilities less cash and cash equivalents (net debt) is compared to adjusted EBITDA". On that basis net debt stood at 9,790 million euros on March 31, 2026, against 9,196 million euros three months earlier, and the ratio moved from 2.5 to 2.6. Cash fell over the same quarter from 1,599 million euros to 1,239 million while the company was buying back its own stock. None of that is distress. It does mean the shareholder return program and the deleveraging story are drawing on the same tap.

The deeper problem is what the capital earns once it is deployed. For the twelve months to March 31, 2026 the filed return on invested capital was 4.9 percent. Translate that: every euro sunk into a clinic, a machine or an acquisition comes back at under five cents a year, which is less than the blended cost of the debt and equity funding it. A business in that position does not compound. It runs, it pays its people, it services its borrowings, and the value of the enterprise stays roughly where it was. That is precisely why the book-value-and-profitability approach is the one lens that comes down to where the shares actually trade while every other approach sits above them. Assets carried at cost are worth their cost when they earn nothing extra.

Which reframes the whole argument. This is not a stock priced for something improbable; today's quote sits below what even a mid single-digit annual decline in operating profit would warrant. The market has already decided the business shrinks. The bear question is whether it is right to, and the most recent quarter gives it material. Operating profit was 286 million euros against 331 million a year earlier, the operating margin 6.2 percent against 6.8 percent, and the Value-Based Care unit swung to a loss of 11 million euros from a small profit. Impairment charges of 109 million euros in the quarter against 12 million a year earlier flatter the underlying comparison somewhat, and a fair reading grants that. The currency effect does not flatter anything: revenue that grew 3 percent at constant rates arrived 6 percent smaller in the reporting currency, and a euro-denominated shareholder cannot spend constant-currency growth.

Underneath sits the structural exposure. The annual report states that "A major portion of our revenues from healthcare are subject to reimbursement rates regulated by governmental authorities", which in the United States means the rate is a legislative and regulatory output rather than a negotiated one. Cost inflation is a private problem; reimbursement is a public decision made on a different clock. And the closest listed comparison is unflattering: DVA converts a smaller trailing revenue base of 13.8 billion dollars into a 15.1 percent operating margin, growing 6.7 percent, roughly double the conversion rate this company achieves. Some of that gap is structural, since a manufacturing arm and a large international clinic footprint both carry thinner economics than U.S. dialysis services alone. Some of it is not. Against all of this, roughly $756 million of equity holdings in other companies sits outside the dialysis operations entirely, and equity-method investees contributed 41 million euros of income in the first quarter, which puts a modest floor under a bad outcome without changing the operating question.

Valuation

The unusual thing about these shares is what the price does not ask for. It does not ask for a new product cycle, a margin expansion or a growth rate the company has never hit. Today's quote sits below what even a mid single-digit annual decline in operating profit would warrant, which is another way of saying the market has priced a business that gradually gets smaller. The embedded operating margin is under three percent. The company currently converts close to nine percent of revenue into operating profit.

Run the price past each family of method and the spread points the same direction. Peer-multiple approaches land furthest above the quote. The cash-flow approaches land above it as well, and so do the earnings-power approaches. Only the lens built from book value and profitability comes down to roughly where the shares trade. Nothing calls the price expensive, which means there is no premium here to argue about; the argument is entirely about whether the discount is deserved.

The filings answer that more directly than any model does. A return on invested capital of 4.9 percent for the twelve months to March 2026 is the reason book value is the binding constraint. When a company earns less on its capital than the capital costs, the assets are worth what they cost and no more, and the methods that price assets and the methods that price earnings power converge toward the same modest answer. That is the whole disagreement, compressed.

Solvency shapes the downside rather than the upside. The company's own leverage measure counts the clinic leases as borrowings, and on that basis it carried 9,790 million euros of net borrowings on March 31, 2026. Operating profit covers the interest bill about 4.4 times over, and the business generates cash rather than consuming it, with 40 million euros of free cash flow in the first quarter against 21 million a year earlier. The share count has been essentially unchanged since 2021, but that window closes before the repurchase programs began, so the trajectory behind is not the trajectory ahead.

Set against the peer set, this is the cheap end of an expensive-looking sector. DVA, the nearest listed dialysis comparison, trades on a business earning a materially wider operating margin, and the broader hospital and care operators in the cohort earn wider margins too. What the reader is weighing here is narrower than the usual valuation question. Every approach agrees the price is not stretched. The open item is whether a company whose returns sit below the cost of its own funding, in a business where legislatures set the price, closes the gap or stays inside it.

Catalysts

Capital return is the clearest scheduled event. The first tranche of a new one billion euro buyback program, worth up to 600 million euros, began on May 28, 2026 and is expected to be completed by December 15, 2026. It follows a program of the same size that ran faster than planned: the first tranche closed on December 29, 2025 and the second, around 415 million euros, was pulled forward to run from January 12 to May 8, 2026, with management attributing the acceleration to cash generation under the strategy presented at its June 2025 capital markets day. Shareholders also voted on May 21, 2026 to cancel treasury shares and reduce the share capital, which is what turns a repurchase into a permanent reduction in the count rather than a parking exercise.

The first-quarter print, published May 5, 2026, is the live operating datapoint. Revenue of 4,612 million euros fell 6 percent as reported and rose 3 percent at constant exchange rates; operating profit of 286 million euros fell 14 percent as reported and 9 percent at constant rates; free cash flow reached 40 million euros against 21 million a year earlier. The segment detail matters more than the headline: Care Delivery held an 8.2 percent operating margin, Care Enablement 6.7 percent, and Value-Based Care turned negative at minus 2.3 percent after carrying a small positive margin a year earlier. Value-Based Care became a separately reported segment during 2025, so its swings are newly visible and will be watched closely.

On the product side, the 5008X CAREsystem has been introduced in U.S. clinics with a full commercial launch underway during 2026, and shareholders approved a dividend of 1.49 euros a share at the same meeting. A machine refresh across a U.S. clinic base of this size is a multi-year installation program rather than a single event, and its effect will show up in the Care Enablement margin line before it shows anywhere else.

Peer Cohorts (Per Segment, With Filing Citations)

Segment and corporate information (reported)

• DVA (DAVITA INC.)
• FY2025 10-K: …incur significant costs in connection with the growth and development of our international operations, including to start up or acquire new operations, we may not be able to operate them profitably on the anticipated timeline, or at all. If we suffer losses in these operations and such losses are sustained and…
• FY2025 10-K: …professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act reports. The Code of Ethics is posted on our website located at http://www.davita.com . We also maintain a Corporate Code of Conduct that applies to all of our…
• ARDT (Ardent Health, Inc.)
• FY2025 10-K: …and appropriately training our employees and management. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing…
• FY2025 10-K: , and protection of health-related and other personal information. For example, the privacy and security regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations…
• THC (TENET HEALTHCARE CORP)
• FY2025 10-K: …and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective as of December 31, 2025 to ensure that material…
• FY2025 10-K: …and is incorporated by reference in accordance with General Instruction G(3) to Form 10-K. Our insider trading policies and procedures are incorporated by reference as Exhibit 19 to this report. ITEM 11. EXECUTIVE COMPENSATION The information required by this Item is set forth under the headings "Executive…
• UHS (UNIVERSAL HEALTH SERVICES, INC.)
• FY2025 10-K: …also "Executive Officers of the Registrant" appearing in Item 1 hereof. ITEM 11. Executi ve Compensation There is hereby incorporated by reference the information to appear under the caption "Executive Compensation" in our Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after…
• FY2025 10-K: …and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by…
• HCA (HCA Healthcare, Inc.)
• FY2025 10-K: Inspections None. 75 PART III Item 10 . Directors, Executive Officers and Corporate Governance The information required by this Item regarding the identity and business experience of our directors and executive officers is set forth under the heading "Nominees for Election" and "Election of Directors" in the…
• FY2025 10-K: …as well as their own whistleblower provisions under which a private party may file a civil lawsuit in state court. We have adopted and distributed policies pertaining to the FCA and relevant state laws. Health Information Privacy, Security and Interoperability The Administrative Simplification Provisions of the…
• SEM (SELECT MEDICAL HOLDINGS CORP)
• FY2025 10-K: …certifications may cause our revenue and profitability to decline; • the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to…
• FY2025 10-K: …information, recognizing different cybersecurity incidents, identifying phishing emails, understanding the appropriate personnel to approach with information or questions, and acceptance of the Company's Information Security Policy. The Company's management is informed of cybersecurity incidents through ongoing…
• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …when the guidance in Topic 270 is applicable, and provides additional guidance on what disclosures should be provided in interim reporting periods. The amendments also require entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The FASB does not…
• FY2025 10-K: …and state laws also require that the Company follow specific labeling, reporting and record-keeping requirements for controlled substances. The Company maintains federal and state controlled substance registrations for each of its facilities that require such registration and materially follows procedures intended to…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …to, or otherwise obtained by OHCA, we anticipate that it will be publicly available and could provide competitors with otherwise unavailable data on the financial operations and reimbursement relationships of our independent subsidiaries. 52 Table of Contents We have filed a Petition in the Superior Court of the…
• FY2025 10-K: …transaction or changes in our Board of Directors could cause the market price of our common stock to decline. Item 1B. UNRESOLVED STAFF COMMENTS None. Item 1C. CYBERSECURITY We utilize information technology that enables our operational leaders to access and share with their peers, both clinical and financial…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.